Company news
Tango Therapeutics, Inc. news in 2023
Tango Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
November 12, 2023
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 7, 2023
Tango Therapeutics to Present at the Jefferies London Healthcare Conference
November 6, 2023
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 17, 2023
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers
September 5, 2023
Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
Tango Therapeutics Announces Updates to Its Board of Directors
August 28, 2023
Tango Therapeutics Announces $80 million Private Placement Financing
August 9, 2023
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 6, 2023
Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers
July 23, 2023
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors
July 9, 2023
Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights
May 8, 2023
Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
April 17, 2023
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers
April 2, 2023
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
March 26, 2023
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
March 13, 2023
Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank
March 9, 2023
Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development
February 27, 2023
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates
January 24, 2023